Eton Pharmaceuticals, Inc. (ETON)

Over the past six months, Eton Pharmaceuticals' stock has increased by 54.91%, reaching $30.96 as of May 4, 2026. Key events include strong Q4 and full-year 2025 financial results, the acquisition and relaunch of HEMANGEOL, and the initiation of a clinical study for ET-700. The company is scheduled to report its first quarter 2026 financial results on May 14, 2026.

Information regarding specific demand seasonality for Eton Pharmaceuticals, Inc.'s products and services is not explicitly detailed. Demand for its products is likely driven by patient diagnoses and ongoing treatment needs rather than typical seasonal consumer patterns, suggesting a relatively stable demand throughout the year.

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases within the Healthcare sector, specifically in the Biotechnology & Drugs industry. The company's portfolio includes commercial rare disease products such as INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, Nitisinone, KHINDIVI, GALZIN, DESMODA, and HEMANGEOL. Eton also has late-stage product candidates like ET-600, Amglidia, ET-700, ET-800, and ZENEO hydrocortisone autoinjector.

Eton Pharmaceuticals, Inc. is headquartered in Deer Park, Illinois, United States, with sales primarily within the United States. The company leverages relationships in the United States and Europe to discover high-potential assets for its pipeline.

Eton Pharmaceuticals focuses on developing and commercializing treatments for rare diseases, emphasizing courage, agility, and efficient execution. The company's reputation has been positively influenced by successful product launches, FDA approvals, and the acquisition of HEMANGEOL. MarketBeat's MarketRank™ analysis indicates a consensus rating of "Hold" with a relatively strong standing within its industry.

Eton Pharmaceuticals, Inc. has a mixed ownership structure including institutional, retail, and individual investors. Institutional owners hold 58.09% of the shares, while insiders own approximately 17.55% to 25.24% of the stock. Public companies and individual investors hold around 58.05%. Major institutional shareholders include Opaleye Management Inc., EcoR1 Capital, LLC, BlackRock, Inc., and Vanguard Group Inc. Sean Brynjelsen, the President and CEO, is a significant individual owner.